Why Do Differences in Clinical Trial Design Make It Hard to Compare COVID-19 Vaccines?
Because of differences in how they were tested in clinical trials, it is difficult to make apples-to-apples comparisons for COVID-19 vaccines.
Research Design
-
Read more: Why Do Differences in Clinical Trial Design Make It Hard to Compare COVID-19 Vaccines? -
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on pharma, health law, and policy issues from August 2020.
-
Read more: Good news for many South African HIV patients—with a big glitch Good news for many South African HIV patients—with a big glitch
By Nir Eyal On Wednesday, South African Health Minister Aaron Motsoaledi announced that, as of January 2015, HIV-positive patients in the country would start receiving free antiretroviral treatment once their CD4 count fell below 500, instead of current threshold of less than 350. Some patient groups would start receiving antiretrovirals immediately upon being diagnosed with…
-
Read more: Times Report Models Worst Practices for Policy Research Reporting Times Report Models Worst Practices for Policy Research Reporting
By Scott Burris I read the Times daily, and so naturally would like to be able to think it deserves to be regarded as a credible “newspaper of record.” Today the paper outdid itself to disappoint, in a story by Sam Dolnick headlined “Pennsylvania Study Finds Halfway Houses Don’t Reduce Recidivism.” In the cause of…